Počet záznamů: 1
Nanomedicines for Breast Cancer Theranostics
- 1.
SYSNO ASEP 0532010 Druh ASEP M - Kapitola v monografii Zařazení RIV C - Kapitola v knize Název Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer Tvůrce(i) Rohiwal, Sonali Suresh (UZFG-Y) ORCID
Tiwari, A. P. (IN)Zdroj.dok. Nanomedicines for Breast Cancer Theranostics. - Amsterdam : Elsevier, 2020 / Thorat N. D. ; Bauer J. - ISBN 978-0-12-820017-9 Rozsah stran s. 331-349 Poč.str. 19 s. Poč.výt. 1000 Poč.str.knihy 438 Forma vydání Tištěná - P Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova animal models ; anti-Cancer drugs ; Breast cancer Vědní obor RIV FD - Onkologie a hematologie Obor OECD Oncology Institucionální podpora UZFG-Y - RVO:67985904 UT WOS 000561991600015 DOI 10.1016/B978-0-12-820016-2.00014-8 Anotace The use of nanotechnology in medicine has a potential impact on human health in terms of its prevention, diagnosis, and treatment of life-threatening diseases, such as cancer. Nanomedicine provides detection of cancer and enhances its treatment efficiency by minimizing the diverse effect associated with the standard therapies. It deals with delivering of various drugs via various mechanisms such as active and passive targeting and triggered release of encapsulated content by solubilization and reduces the risk of systemic side effects. Several experimental challenges need to be conquered to address from bench to besides. Herein, we discussed the clinical translations of nanomedicines its development and commercialization in terms of various drugs. Furthermore, the issues related to development of materials is explored in detail including large-scale manufacturing, biological challenges, biocompatibility and safety, government regulations, and several animal nonpredictive animal models in comparison to current therapies. Pracoviště Ústav živočišné fyziologie a genetiky Kontakt Jana Zásmětová, knihovna@iapg.cas.cz, Tel.: 315 639 554 Rok sběru 2021
Počet záznamů: 1